Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

LY-320135

Benzofuran CB1 antagonist, Ki 224 nM and more than 70-fold selective over CB2.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₄H₁₇NO₄

CAS 176977-56-3

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
383.40 g/mol

Updated on

In plain terms

LY-320135 blocks the CB1 receptor without resembling other known blockers chemically. It was used to reveal an unexpected behaviour of this receptor: under certain conditions it can stimulate an enzyme it normally inhibits. It is a laboratory tool; no study in humans was found.

Receptors and activity

Target network

CB1AntagonistKi = 224 nMbinding at CB1 stably expressed in a cell line (224 nM) and on cerebellar membranes (203 nM); species not specified in the abstract; reverses the inhibition of adenylate cyclase by anandamide
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to LY-320135: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of LY-320135.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1AntagonistKi = 224 nM44 out of 100

    Felder et al., J Pharmacol Exp Ther 1998 (new tab) · binding at CB1 stably expressed in a cell line (224 nM) and on cerebellar membranes (203 nM); species not specified in the abstract; reverses the inhibition of adenylate cyclase by anandamide

  2. CB2Binding (function not established)no measured value cited

    Ki greater than 10 µM (stable line and spleen membranes); CB1 selectivity greater than 70-fold (Felder et al. 1998)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

LY-320135 is a CB1 receptor antagonist described in 1998 by Felder and colleagues, with a benzofuran structure. Its selectivity is clear: Ki 224 nM at CB1 stably expressed in cell lines versus above 10 µM at CB2, more than 70-fold, with similar values on cerebellum and spleen membranes. Its main interest is methodological. By treating CHO cells expressing CB1 with pertussis toxin, the authors attenuated anandamide-mediated inhibition of adenylate cyclase and unmasked a stimulatory effect of anandamide on the enzyme; LY320135 blocked this stimulatory component, attributing it to the CB1 receptor (Felder et al. 1998). The compound also blocks the WIN 55212-2-mediated inhibition of N-type calcium channels and activation of inwardly rectifying potassium channels. The authors describe it as a promising lead for new cannabinoid antagonists of novel structure. These results come from cells and membranes; no study in whole animals or in humans was found.

History

Source
An entirely synthetic compound with no natural occurrence. It is known as a pharmacological research reagent; no clinical development or human use was found in the sources consulted.

Origin

Research tool

No biological pathway: LY-320135 is a synthetic compound with a benzofuran core, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

LY-320,135 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
4-[6-methoxy-2-(4-methoxyphenyl)-1-benzofuran-3-carbonyl]benzonitrile
Other names
LY320135 · LY 320135

Identifiers

Formula
C₂₄H₁₇NO₄
CAS
176977-56-3
PubChem CID
5311257(new tab)
InChIKey
RYNSGDFWBJWWSZ-UHFFFAOYSA-N
SMILES
COC1=CC=C(C=C1)C2=C(C3=C(O2)C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)C#N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.